Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk Meeting Abstract


Authors: Shah, R.; Botteman, M.; Kwon, Y.; Gooden, K. M.; Cella, D.; Motzer, R.
Abstract Title: Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk
Meeting Title: ISPOR 2019
Journal Title: Value in Health
Volume: 22
Issue: Suppl. 2
Meeting Dates: 2019 May 18-22
Meeting Location: New Orleans, LA
ISSN: 1098-3015
Publisher: Elsevier Science, Inc.  
Date Published: 2019-05-01
Start Page: S106
Language: English
ACCESSION: WOS:000472670100337
DOI: 10.1016/j.jval.2019.04.385
PROVIDER: wos
Notes: Meeting Abstract: PCN264 -- Source: Wos
Altmetric Score
MSK Authors
  1. Robert Motzer
    801 Motzer